About P&T JournalContacts:
Statement of Purpose
Guidelines for Authors
In a survey conducted by the authors, physicians responded that even though they felt that it was not their responsibility to advise their senior patients on the government’s prescription drug benefit, many reported rendering such advice anyway.
Bruce Pitts, MD, MBA, Angela Dominelli, PhD, RPh, and Shamima Khan, MBA, PhD
Topics include the rivastigmine transdermal system (Exelon Patch) for mild-to-moderate dementia of the Alzheimer’s type and for mild-to-moderate dementia associated with Parkinson’s disease; armodafinil (Nuvigil) for improving wakefulness; and ambrisentan (Letairis) for pulmonary arterial hypertension.
Marvin M. Goldenberg, PhD, RPh, MS
The blog called Master of Irony has the title that best sums up the changing nature of communication between doctors and patients: by posting their real feelings in cyberspace—away from the glare of the white lights and lab coats—bloggers have the potential to improve outcomes, compliance, and trust, in some cases all before uttering a single spoken word.
Continuing Education Credit
Dr. Casey reviews the causes of behavioral disturbance in patients with Alzheimer’s disease and other forms of dementia, with an emphasis on the various available therapies, including atypical antipsychotic agents, mood stabilizers, antidepressants, benzodiazepines, and sleep medications.
David A. Casey, MD
David Nash, MD, MBA, discusses a controversial report by Milliman, Inc., in which the costs of innovative therapies are considered relatively minor—too good to be true?
David B. Nash, MD, MBA
Matthew Grissinger, RPh, FASCP, explains the problems that arise when tubing for blood pressure monitoring devices is inadvertently connected to an IV port.
Matthew Grissinger, RPh, FASCP
Stephen Barlas uncovers an additional duty that is being forced on pharmacists: making sure that prescription pads are “tamper-proof.”
From amiodarone to valproate, P&T presents the latest information about FDA approvals, new indications, and industry updates.
Ramoplanin: A Promising Treatment Option for Clostridium difficile–Associated Diarrhea and Vancomycin-Resistant Enterococcus
The authors discuss ramoplanin for Clostridium difficile– associated diarrhea and vancomycin-resistant Enterococcus.
Christopher R. Emerson, PharmD, and Nino Marzella, BS, PharmD